Oganovo Announces World’s First Commercially Available 3D Printed Liver Tissue

Organovo has announced the full commercial release of the exVive3DTM Human Liver Tissue for preclinical drug discovery testing. 

Initially, clients will be able to access the technology through Organovo’s contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.

Organovo’s exVive3D Liver Models are bioprinted, living 3D human liver tissues consisting of primary human hepatocytes, stellate, and endothelial cell types, which are found in native human liver. The exVive3D Liver Models are created using Organovo’s proprietary 3D bioprinting technology that builds functional living tissues containing precise and reproducible architecture. The tissues are functional and stable for at least 42 days, which enables assessment of drug effects over study durations that well beyond those offered by industry-standard 2D liver cell culture systems. 

Read more at ENGINEERING.com

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest

Related Articles

Keep up to date on 3D Printing technologies

We're learning a lot about 3D printing, and So will you.

Subscribe to our mailing list and make better 3D print decisions.